Skip to main content
. 2014 Jun 2;8:77–80. doi: 10.4137/CMO.S14569

Table 1.

Different studies testing vismodegib.

STUDY PHASE PATIENTS OR (%) CR (%) PR (%) MR (MONTHS) TOXICITY (GRADE 3 OR 4)
Lorusso et al31 I 33/68 58 6 48.5 12.8 6 patients
Lorusso et al32 Ib 67 30%
Tang et al34 II 41 100 Some 4%
Sekulic et al32 (ERIVANCE) II 104 43 21 7.9
Chang et al35 119 46.4% and 30.8%

Abbreviations: OR, overall response; CR, complete response; PR, partial response; MR, median duration of response.